Dynamics of plasma active GLP-1 versus insulin and glucose concentrations during GLP-1 infusion in rat model of postprandial hyperglycemia

Endocrine Journal

Volumn 58, Issue 8, 2011, Pages 691-698

  Eiki, Jun ichi ^a,b   Yada, Toshihiko ^b,c  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

Author keywords

GLP 1; Glucose; Insulin; Rat

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HORMONE BLOOD LEVEL; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; JUGULAR VEIN; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; RAT;

ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INFUSIONS, INTRAVENOUS; INSULIN; KINETICS; MALE; OSMOLAR CONCENTRATION; RATS; RATS, WISTAR;

EID: 80052570816     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K11E-096     Document Type: Article

References (27)

1. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3: 153-165.
2. 2+ channel activity. Endocrinology 133: 1685-1692.
3. 2+ in rat pancreatic beta-cells. Diabetes 45: 295-301.
4. Henquin J-C (2004) Pathways in Beta-Cell Stimulus- Secretion Coupling as Targets for Therapeutic Insulin Secretagogues. Diabetes 53: S48-S58.
5. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
6. Weir GC, Mojsov S, Hendrick GK, Habener JF (1989) Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342.
7. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S (1989) Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38: 902-905.
8. Goke R, Fehmann HC, Richter G, Trautmann M, Goke B (1989) Interaction of glucagon-like peptide-1(7-36) amide and somatostatin-14 in RINm5F cells and in the perfused rat pancreas. Pancreas 4: 668-673.
9. D'Alessio DA, Fujimoto WY, Ensinck JW (1989) Effects of glucagonlike peptide I-(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes 38: 1534-1538.
10. Shima K, Hirota M, Ohboshi C (1988) Effect of glucagon- like peptide-1 on insulin secretion. Regul Pept 22: 245-252.
11. Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616-619.
12. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Niijima A (1996) The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 61: 149-154.
13. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A (1996) Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271: E808-813.
14. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K, Uchida K (2004) Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110: 36-43.
15. 2+ in rat nodose ganglion neurons. Auton Neurosci 102: 39-44.
16. Balkan B, Li X (2000) Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279: R1449-1454.
17. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, Hellstrom PM (1999) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277: R910-916.
18. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B (1995) Glucagon-like peptide-1 and glucosedependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117-126.
19. Lerche S, Soendergaard L, Rungby J, Moeller N, Holst JJ, Schmitz OE, Brock B (2009) No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol 71: 500-506.
20. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagonlike peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88: 2719-2725.
21. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91: 4612-4619.
22. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89: 2078-2084.
23. Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S (2011) (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino] acetyl}-pyrrolidin e-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor. Eur J Pharmacol 655: 99-107.
24. Asakawa T, Moritoh Y, Kataoka O, Suzuki N, Takeuchi K, Odaka H (2009) A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci 85: 122-126.
25. Hansen L, Deacon CF, Orskov C, Holst JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356-5363.
26. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439.
27. Carlsson PO, Iwase M, Jansson L (1999) Stimulation of intestinal glucoreceptors in rats increases pancreatic islet blood flow through vagal mechanisms. Am J Physiol 276: R233-236.